Lil­ly's Covid-19 part­ner Ab­Cellera is tak­ing a new an­ti­body in­to the clin­ic in the hopes it can tack­le all vari­ants

As the virus be­hind the Covid-19 pan­dem­ic con­tin­ues to mu­tate in­to sev­er­al vari­ants of con­cern, the com­pa­ny be­hind Eli Lil­ly’s bam­lanivimab an­ti­body treat­ment is look­ing to stay ahead of the curve.

Ab­Cellera is push­ing for­ward with a new mon­o­clon­al an­ti­body can­di­date for Covid-19 that it says can neu­tral­ize all cur­rent­ly known vari­ants, mov­ing the pro­gram known as LY-CoV1404 in­to its first clin­i­cal tri­als, the Van­cou­ver-based biotech said Tues­day morn­ing. The pro­gram will join Lil­ly’s on­go­ing Blaze-4 study where it will be eval­u­at­ed in mild to mod­er­ate Covid-19 cas­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER